Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07291687

tDCS as Treatment for Motor Function

Previous preliminary results are sufficiently impressive to suggest that tDCS stimulation does have the potential to improve motor function when that ability is trained during stimulation. In the proposed study, the investigation will assess whether walking sessions combined with tDCS lead to improvements in motor function: gait, articulation, eye gaze, and motor dexterity. In addition, the investigators wish to examine if such results can be replicated in people with other conditions, such as cortical basal syndrome, and Parkinson's disease.

Recruiting

Interested in participating?

Request Info

Key information

About this study

Previous preliminary results are sufficiently impressive to suggest that tDCS stimulation does have the potential to improve motor function when that ability is trained during stimulation. In the proposed study, the investigators will assess whether walking sessions combined with tDCS lead to improvements in motor function: gait, articulation, eye gaze, and motor dexterity. In addition, the investigators wish to examine if such results can be replicated in people with other conditions, such as cortical basal syndrome, and Parkinson's disease. The rationale for including people living with these conditions is the overlap in motor and cortical network dysfunction observed across these disorders. All three conditions involve impairment of motor initiation, gait, coordination, and executive motor control due to degeneration in frontal-subcortical pathways. This extension will also allow for comparison of stimulation responsiveness across related diagnostic groups and provide insight into disease-specific factors influencing motor recovery potential.

Previous tDCS studies have found significant results with sample sizes between 10-20 participants for a two-round study comparing training sessions with real tDCS versus sessions done without tDCS. However, the investigators plan to recruit 30 participants living with each condition as this will allow us to examine results per group, but also how the individual groups compare.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 1. Participants must be able to walk unassisted, or with the assistance of a walker or cane, and be individuals who walk daily.
  • Participants should have a sufficient level of English to be able to express themselves verbally, be able to read and follow instructions.

Exclusion criteria

  • 3. Individuals with metal implants within the brain such as shunts will be excluded.

Treatment and study plan

Transcranial direct current stimulation (tDCS)

Device

The Crossover design will enable us to use each participant as their own control.

Stimulation Arm

Device

Participants will be exposed to the brain stimulation protocol while undergoing certain motor task during the training sessions.

Primary outcomes

  1. Gait speed

    Time frame: Measures collected at three points each round: baseline in week 1, post-treatment at the final stimulation session, and follow-up two weeks after the final session.

    Within each round, scores from the final week and final session of real tDCS stimulation will be compared to performance during the first week and final sham tDCS session to check for significant improvement. Our primary outcome measures will be those found for gait; for example, a faster walking time subsequent to tDCS stimulation compared to the placebo baseline. Participants will also return two weeks later for a post-stimulation evaluation to check if improvement was maintained. To check if the arrangement of electrodes impacts the effect, times from the final tDCS session of each round will be compared.

Secondary outcomes

  1. Articulation Quality (Clinician-Rated Speech Production on Word and Sentence Repetition)

    Time frame: Measures collected at three points each round: baseline in week 1, post-treatment at the final stimulation session, and follow-up two weeks after the final session.

    Articulation will be assessed using a clinician-administered repetition task involving single words and short sentences. Speech production quality will be rated by the clinician using a standardized 5-point articulation quality scale (1 = severely distorted, 5 = normal/near-normal production). The reported value will be the rating score.

  2. Eye-Gaze Control (Clinician-Rated Ability to Track a Moving Target)

    Time frame: Measures collected at three points each round: baseline in week 1, post-treatment at the final stimulation session, and follow-up two weeks after the final session.

    Eye-gaze performance will be evaluated using a bedside oculomotor task. Participants are asked to follow a moving pencil with their eyes while keeping their head still. A clinician will rate eye-gaze control on a standardized 3-point scale (0 = unable, 1 = inconsistent, 2 = consistent and accurate). The reported value will be the rating score.

Study contacts

Contact information is provided by the study sponsor or research team.

Alice Zhang, B.Sc

CONTACT

[email protected]

(416) 785-2500 ext. 2522

Tyler Roncero, Ph.D

CONTACT

[email protected]

T (416) 785-2500 ext. ext. 2522

Sponsors and collaborators

Lead sponsor

Baycrest

Other

Registry information

Official study title

Transcranial Direct Current Stimulation as a Treatment for Motor Function in Participants Living With Progressive Supranuclear Palsy, Corticalbasal Syndrome Degeneration, or Parkinson's Disease

Acronym: PSP

Important dates

Study start
2025
Primary completion
2028
Study completion
2030
First posted
Dec 18, 2025
Registry last updated
Dec 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.